Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Deininger

Hematology Milwaukee, WI Medical Doctor

NPI 1932115524 CMS profile 132483

9200 W Wisconsin Ave, Milwaukee, WI 53226

Open in the dashboard

General payments

$146,068

77 records reported · program years 2019–2025

Research payments

$32,167

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,015,351 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Michael Deininger of Milwaukee, WI is reported in the CMS Open Payments database as having received $146,068 across 77 general payments and $32,167 in research payments paid to them. Separately, studies naming them as principal investigator received $2,015,351 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,857 6
2025 Research $324 1
2024 General $7,396 11
2024 Research $2,557 4
2023 General $17,968 16
2023 Research $7,551 2
2022 General $34,376 11
2022 Research $5,840 9
2021 General $15,818 5
2021 Research $10,250 9
2020 General $16,973 6
2020 Research $5,250 4
2019 General $24,681 22
2019 Research $395 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Deininger
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Michael Deininger were reported at $28,857. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Michael Deininger Hematology median Middle half National median
2019 $24,681 $1,012 $122–$9,834 $163
2020 $16,973 $1,475 $115–$9,198 $114
2021 $15,818 $1,470 $125–$7,444 $132
2022 $34,376 $1,371 $139–$8,471 $149
2023 $17,968 $1,295 $147–$11,010 $160
2024 $7,396 $1,286 $146–$9,230 $164
2025 $28,857 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $42,465 19 payments
  2. Blueprint Medicines Corporation $28,111 17 payments
  3. Genzyme Corporation $24,323 2 payments
  4. Pfizer Inc. $17,522 10 payments
  5. Novartis Pharma AG $11,436 8 payments
  6. Incyte Corporation $8,480 11 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $5,656 4 payments
  8. GlaxoSmithKline, LLC. $5,200 1 payment
  9. Sanofi US Services Inc. $2,211 1 payment
  10. Promega Corporation $591 2 payments
  11. Other $73 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $117,960 24 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,750 9 payments
  3. Travel and Lodging $5,991 16 payments
  4. Honoraria $4,200 1 payment
  5. Food and Beverage $2,123 26 payments
  6. Education $43 1 payment
Products named General payments · program years 2019–2025
  1. AYVAKIT Gastroenterology $26,534 3 payments
  2. BOSULIF $17,522 10 payments
  3. SCEMBLIX $11,557 9 payments
  4. ABL002 $8,843 3 payments
  5. TASIGNA Hematology $5,980 4 payments
  6. ICLUSIG Oncology $4,031 2 payments
  7. TASIGNA Oncology $2,620 1 payment
  8. GLEEVEC $2,363 1 payment
  9. ICLUSIG Oncology $1,625 2 payments
  10. AYVAKIT Oncology / Rare Diseases $108 2 payments
  11. Other $73 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $22,380 22 payments
  2. Novartis Pharmaceuticals Corporation $9,233 6 payments
  3. Novartis Pharma AG $554 2 payments

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record